Get the Stockscreener App
29.04
6.35%
-1.97
Alkermes Plc stock is traded at $29.04, with a volume of 5.75M.
It is down -6.35% in the last 24 hours and down -9.08% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$31.01
Open:
$30.22
24h Volume:
5.75M
Relative Volume:
2.46
Market Cap:
$4.79B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
14.89
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
-11.71%
1M Performance:
-9.08%
6M Performance:
-5.16%
1Y Performance:
+2.43%
1-Day Range:
$28.67
$30.36
1-Week Range:
$27.49
$34.45
52-Week Range:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
29.04 | 5.12B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
120.82 | 53.39B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.29 | 44.99B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.59 | 44.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
25.41 | 29.30B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
466.40 | 19.91B | 3.08B | 1.24B | 1.07B | 25.61 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-25 | Initiated | Truist | Buy |
| Sep-26-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jun-17-25 | Upgrade | UBS | Neutral → Buy |
| May-28-25 | Initiated | Needham | Buy |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
How strong is Alkermes plc (8AK) stock earnings growthBull Run & Risk Controlled Swing Trade Alerts - newser.com
Applying Elliott Wave Theory to Alkermes plcQuarterly Market Review & Long-Term Growth Portfolio Plans - newser.com
What moving averages say about Alkermes plc2025 Top Gainers & Technical Confirmation Trade Alerts - newser.com
How Alkermes plc (8AK) stock valuation compares with sectorTrade Analysis Report & Weekly High Return Stock Forecasts - newser.com
What data driven models say about Alkermes plc’s futureNew Guidance & Low Risk Growth Stock Ideas - newser.com
Trading Systems Reacting to (ALKS) Volatility - news.stocktradersdaily.com
Avadel (AVDL) Soars to 10-Year High on Brewing Bidding War - Finviz
Risk vs reward if holding onto Alkermes plcIPO Watch & Risk Managed Investment Strategies - newser.com
How high can Alkermes plc stock goTrade Ideas & Daily Stock Momentum Reports - newser.com
Comparing Alkermes plc in custom built stock radarsOptions Play & AI Powered Market Entry Strategies - newser.com
Will Alkermes plc stock rally after Fed decisionsShare Buyback & Growth Focused Stock Reports - newser.com
Avadel Gets Acquisition Proposal From Lundbeck Weeks After Inking Agreement With Alkermes - MSN
STATE STREET CORP's Strategic Acquisition of Alkermes PLC Shares - GuruFocus
Alkermes responds to potential rival bid for Avadel from Lundbeck By Investing.com - Investing.com Nigeria
Another Bidding War As Lundbeck Swoops In On Alkermes/Avadel Deal - Citeline News & Insights
To Wall Street, a new bidding war puts Alkermes in a tough spot - BioPharma Dive
Avadel Pharmaceuticals Attracts Rival Bids In Buyout Showdown - Finimize
Avadel Faces Competing Bids From Lundbeck And Alkermes - Finimize
Alkermes (ALKS) Positioned for Strategic Acquisition - GuruFocus
Alkermes (ALKS) Shares Decline Amid Market Activity - GuruFocus
Is Alkermes plc forming a bottoming base2025 Support & Resistance & Low Risk Entry Point Guides - newser.com
Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal - Benzinga
Is Alkermes plc stock ready for breakoutJuly 2025 Drop Watch & Low Risk Profit Maximizing Plans - Fundação Cultural do Pará
Alkermes (ALKS) Stock Experiences Notable Decline - GuruFocus
Avadel Pharmaceuticals Receives Unsolicited Acquisition Proposal From Lundbeck - MarketScreener
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal - Finviz
Avadel Considers Lundbeck's Proposal Amid Alkermes Agreement (AL - GuruFocus
Alkermes (ALKS) Evaluates Options Following Avadel Pharmaceutica - GuruFocus
Alkermes Response to Avadel Announcement - The AI Journal
Alkermes weighs options after Lundbeck's higher bid for Avadel - MarketScreener
Alkermes responds to competing offer for Avadel from Lundbeck - StreetInsider
Alkermes (NASDAQ: ALKS) notes Avadel must give 5 Business Days’ notice, negotiate - Stock Titan
Is Alkermes plc (8AK) stock considered safe havenJuly 2025 Analyst Calls & Long Hold Capital Preservation Plans - Fundação Cultural do Pará
Avadel climbs as Lundbeck outbids Alkermes in latest bidding war - Seeking Alpha
Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal - Yahoo Finance
Wells Fargo Lowers Price Target for Alkermes (ALKS) to $37 | ALKS Stock News - GuruFocus
Is Alkermes plc (8AK) stock at risk of policy regulationTrend Reversal & Expert Verified Stock Movement Alerts - newser.com
Alkermes at Stifel 2025: Strategic Insights on Narcolepsy Drug - Investing.com
Alkermes Shares Phase 2 Results of Orexin 2 Receptor Agonist in Narcolepsy Type 2 - Sleep Review
Is Alkermes plc a good long term investmentVolatility Trading Techniques & Register for the Next Free Workshop - earlytimes.in
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.58%
4.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):